P. Danaietash

Effect of the urotensin receptor antagonist palosuran on albuminuria in hypertensive patients with type 2 diabetic nephropathy: results from the PROLONG proof-of-concept study

S. Hadjadj, G. Remuzzi, H. Krum, 2008 .

Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy

S. Hadjadj, G. Remuzzi, H. Krum, 2010, Hypertension.

Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan

Ji-Guang Wang, K. Narkiewicz, I. Kantola, 2022, Journal of clinical hypertension.

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension

J. Ménard, B. Flamion, P. Verweij, 2020, Hypertension.

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

F. Hampel, P. Ratner, C. Andrews, 2017, Allergy, Asthma & Clinical Immunology.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

P. Gosse, S. Oparil, Pankaj Gupta, 2022, The Lancet.